

Eliseo Pascual

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3859133/publications.pdf>

Version: 2024-02-01

88
papers

6,741
citations

147786

31
h-index

64791

79
g-index

95
all docs

95
docs citations

95
times ranked

4459
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | 2016 updated EULAR evidence-based recommendations for the management of gout. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 29-42. | 0.9 | 1,096 |
| 2 | EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee For International Clinical Studies Including Therapeutics (ESCISIT). <i>Annals of the Rheumatic Diseases</i> , 2006, 65, 1312-1324. | 0.9 | 1,079 |
| 3 | Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. <i>Arthritis and Rheumatism</i> , 2005, 52, 1766-1772. | 6.7 | 612 |
| 4 | European League Against Rheumatism recommendations for calcium pyrophosphate deposition. Part I: terminology and diagnosis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 563-570. | 0.9 | 418 |
| 5 | Suppressor T-cell abnormality in idiopathic systemic lupus erythematosus. <i>Clinical Immunology and Immunopathology</i> , 1976, 6, 192-199. | 2.0 | 303 |
| 6 | Gout: why is this curable disease so seldom cured?. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1765-1770. | 0.9 | 228 |
| 7 | 2018 updated European League Against Rheumatism evidence-based recommendations for the diagnosis of gout. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 31-38. | 0.9 | 225 |
| 8 | “Crystal Clear” Sonographic Assessment of Gout and Calcium Pyrophosphate Deposition Disease. <i>Seminars in Arthritis and Rheumatism</i> , 2006, 36, 197-202. | 3.4 | 202 |
| 9 | Synovial Fluid Analysis for Diagnosis of Intercritical Gout. <i>Annals of Internal Medicine</i> , 1999, 131, 756-759. | 3.9 | 200 |
| 10 | EULAR recommendations for calcium pyrophosphate deposition. Part II: Management. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 571-575. | 0.9 | 193 |
| 11 | Persistence of monosodium urate crystals and low-grade inflammation in the synovial fluid of patients with untreated gout. <i>Arthritis and Rheumatism</i> , 1991, 34, 141-145. | 6.7 | 172 |
| 12 | Improving cardiovascular and renal outcomes in gout: what should we target?. <i>Nature Reviews Rheumatology</i> , 2014, 10, 654-661. | 8.0 | 169 |
| 13 | Ultrasound-detected musculoskeletal urate crystal deposition: which joints and what findings should be assessed for diagnosing gout?. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1522-1528. | 0.9 | 155 |
| 14 | Time required for disappearance of urate crystals from synovial fluid after successful hypouricaemic treatment relates to the duration of gout. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 1056-1058. | 0.9 | 135 |
| 15 | Analysis for crystals in synovial fluid: training of the analysts results in high consistency. <i>Annals of the Rheumatic Diseases</i> , 2005, 64, 612-615. | 0.9 | 106 |
| 16 | Most calcium pyrophosphate crystals appear as non-birefringent. <i>Annals of the Rheumatic Diseases</i> , 1999, 58, 582-584. | 0.9 | 94 |
| 17 | Synovial fluid analysis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2005, 19, 371-386. | 3.3 | 89 |
| 18 | Understanding How the Diagnostic Delay of Spondyloarthritis Differs Between Women and Men: A Systematic Review and Metaanalysis. <i>Journal of Rheumatology</i> , 2017, 44, 174-183. | 2.0 | 85 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 19 | Mechanisms of crystal formation in gout—a structural approach. <i>Nature Reviews Rheumatology</i> , 2015, 11, 725-730. | 8.0 | 79 |
| 20 | Silent Monosodium Urate Crystal Deposits Are Associated With Severe Coronary Calcification in Asymptomatic Hyperuricemia: An Exploratory Study. <i>Arthritis and Rheumatology</i> , 2016, 68, 1531-1539. | 5.6 | 74 |
| 21 | Gout, Hyperuricemia, and Crystal-Associated Disease Network Consensus Statement Regarding Labels and Definitions for Disease Elements in Gout. <i>Arthritis Care and Research</i> , 2019, 71, 427-434. | 3.4 | 73 |
| 22 | Why is gout so poorly managed?. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 1269-1270. | 0.9 | 72 |
| 23 | Gout, Hyperuricaemia and Crystal-Associated Disease Network (G-CAN) consensus statement regarding labels and definitions of disease states of gout. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1592-1600. | 0.9 | 72 |
| 24 | Synovial fluid analysis for crystals. <i>Current Opinion in Rheumatology</i> , 2011, 23, 161-169. | 4.3 | 62 |
| 25 | Mononuclear cells in human synovial fluid. Identification of lymphoblasts in rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 1976, 19, 743-748. | 6.7 | 47 |
| 26 | Acute gouty arthritis without urate crystals identified on initial examination of synovial fluid. <i>Arthritis and Rheumatism</i> , 1975, 18, 603-612. | 6.7 | 43 |
| 27 | Synovial Fat Necrosis Associated with Ischemic Pancreatic Disease. <i>Arthritis and Rheumatism</i> , 1979, 22, 547-553. | 6.7 | 41 |
| 28 | An Audit of the Variability of Diagnosis and Management of Gout in the Rheumatology Setting. <i>Journal of Clinical Rheumatology</i> , 2011, 17, 349-355. | 0.9 | 41 |
| 29 | Cardiovascular risk of patients with gout seen at rheumatology clinics following a structured assessment. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1263-1268. | 0.9 | 38 |
| 30 | Febuxostat. <i>Nature Reviews Drug Discovery</i> , 2009, 8, 191-192. | 46.4 | 36 |
| 31 | Therapeutic advances in gout. <i>Current Opinion in Rheumatology</i> , 2007, 19, 122-127. | 4.3 | 34 |
| 32 | Gout: The mechanism of urate crystal nucleation and growth. A hypothesis based in facts. <i>Joint Bone Spine</i> , 2013, 80, 1-4. | 1.6 | 27 |
| 33 | Gout: optimizing treatment to achieve a disease cure. <i>Therapeutic Advances in Chronic Disease</i> , 2016, 7, 135-144. | 2.5 | 27 |
| 34 | Gout. <i>Current Opinion in Rheumatology</i> , 2004, 16, 282-286. | 4.3 | 24 |
| 35 | Methotrexate Is an Option for Patients With Refractory Calcium Pyrophosphate Crystal Arthritis. <i>Journal of Clinical Rheumatology</i> , 2012, 18, 234-236. | 0.9 | 24 |
| 36 | Therapy for CPPD: Options and Evidence. <i>Current Rheumatology Reports</i> , 2018, 20, 31. | 4.7 | 24 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Identifying Potential Classification Criteria for Calcium Pyrophosphate Deposition Disease: Item Generation and Item Reduction. <i>Arthritis Care and Research</i> , 2022, 74, 1649-1658. | 3.4 | 23 |
| 38 | Gout treatment: should we aim for rapid crystal dissolution?. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 635-637. | 0.9 | 22 |
| 39 | Challenges to conquer from the gender perspective in medicine: The case of spondyloarthritis. <i>PLoS ONE</i> , 2018, 13, e0205751. | 2.5 | 20 |
| 40 | Hyperuricemia and gout. <i>Current Opinion in Rheumatology</i> , 1994, 6, 454. | 4.3 | 18 |
| 41 | Severe gout: Strategies and innovations for effective management. <i>Joint Bone Spine</i> , 2017, 84, 541-546. | 1.6 | 18 |
| 42 | Joint nociceptor nerve activity and pain in an animal model of acute gout and its modulation by intra-articular hyaluronan. <i>Pain</i> , 2018, 159, 739-748. | 4.2 | 18 |
| 43 | Gout update: from lab to the clinic and back. <i>Current Opinion in Rheumatology</i> , 2000, 12, 213-218. | 4.3 | 17 |
| 44 | Anakinra for a refractory case of intermittent hydrarthrosis with a TRAPS-related gene mutation. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 155-155. | 0.9 | 14 |
| 45 | Acute Hip Monoarthritis in a Patient Treated With Isotretinoin. <i>Journal of Clinical Rheumatology</i> , 2006, 12, 105-106. | 0.9 | 13 |
| 46 | Criteria for Gout Diagnosis?. <i>Journal of Rheumatology</i> , 2013, 40, 356-358. | 2.0 | 12 |
| 47 | Most needle-shaped calcium pyrophosphate crystals lack birefringence. <i>Rheumatology</i> , 2019, 58, 1095-1098. | 1.9 | 12 |
| 48 | Managing Gout in the Patient with Renal Impairment. <i>Drugs and Aging</i> , 2018, 35, 263-273. | 2.7 | 10 |
| 49 | Febuxostat for Patients With Gout and Severe Chronic Kidney Disease: Which Is the Appropriate Dosage? Comment on the Article by Saag et al. <i>Arthritis and Rheumatology</i> , 2016, 68, 2563-2564. | 5.6 | 9 |
| 50 | Interleukin-6 pathway blockade as an option for managing refractory cases of crystal arthritis: Two cases report. <i>Joint Bone Spine</i> , 2018, 85, 377-378. | 1.6 | 9 |
| 51 | Acute arthritis following SARS-CoV-2 infection. <i>Journal of Medical Virology</i> , 2021, 93, 661-661. | 5.0 | 9 |
| 52 | Gout: new advances in the diagnosis and management of an old disease. <i>International Journal of Clinical Rheumatology</i> , 2009, 4, 203-220. | 0.3 | 8 |
| 53 | Current advances in therapies for calcium pyrophosphate crystal arthritis. <i>Current Opinion in Rheumatology</i> , 2016, 28, 140-144. | 4.3 | 8 |
| 54 | Manifestations articulaires de l'arthrose. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2006, 73, 362-368. | 0.0 | 7 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 55 | Response: Renal dosing of allopurinol results in suboptimal gout care by T Neogi <i>et al</i> . <i>Annals of the Rheumatic Diseases</i> , 2017, 76, e2-e2. | 0.9 | 7 |
| 56 | Impaired Trunk Posture in Women With Fibromyalgia. <i>Spine</i> , 2018, 43, 1536-1542. | 2.0 | 7 |
| 57 | Synovial fluid leukocyte count in asymptomatic hyperuricaemia with crystal deposition: a proof-of-concept study. <i>Rheumatology</i> , 2019, 58, 1104-1105. | 1.9 | 7 |
| 58 | Reviewing Disease Activity Indices in Spondyloarthritis From the Sex Perspective: A Systematic Review and Metaanalysis. <i>Journal of Rheumatology</i> , 2021, 48, 1395-1404. | 2.0 | 7 |
| 59 | An Unusual Tophus. <i>New England Journal of Medicine</i> , 2015, 372, e6. | 27.0 | 6 |
| 60 | Methotrexate: should it still be considered for chronic calcium pyrophosphate crystal disease?. <i>Arthritis Research and Therapy</i> , 2015, 17, 89. | 3.5 | 6 |
| 61 | Sex and Gender Interactions in the Lives of Patients with Spondyloarthritis in Spain: A Quantitative-qualitative Study. <i>Journal of Rheumatology</i> , 2017, 44, 1429-1435. | 2.0 | 6 |
| 62 | Normal Initial Magnetic Resonance Imaging in Aseptic Bone Necrosis of the Knee. <i>Journal of Clinical Rheumatology</i> , 2008, 14, 101-104. | 0.9 | 5 |
| 63 | Progresses in the imaging of calcium pyrophosphate crystal disease. <i>Current Opinion in Rheumatology</i> , 2020, 32, 140-145. | 4.3 | 5 |
| 64 | Editorial: Decreasing Crystal-Induced Consternation: New Methods of Crystal Identification. <i>Arthritis and Rheumatology</i> , 2016, 68, 1574-1577. | 5.6 | 4 |
| 65 | Mixed Crystal Disease: A Tale of 2 Crystals. <i>Journal of Rheumatology</i> , 2020, 47, 1158-1159. | 2.0 | 4 |
| 66 | Calcium pyrophosphate crystal deposition. <i>International Journal of Clinical Rheumatology</i> , 2011, 6, 677-688. | 0.3 | 3 |
| 67 | Is Remission a Valid Target for Gout?. <i>Journal of Rheumatology</i> , 2020, 47, 4-5. | 2.0 | 3 |
| 68 | International position paper on febuxostat. <i>Clinical Rheumatology</i> , 2010, 29, 835. | 2.2 | 3 |
| 69 | Birefringent crystals deposition and inflammasome expression in human atheroma plaques by levels of uricemia. <i>Joint Bone Spine</i> , 2022, 89, 105423. | 1.6 | 3 |
| 70 | Infectious Arthritis of a Lumbar Facet Joint. <i>Journal of Clinical Rheumatology</i> , 1999, 5, 22-24. | 0.9 | 2 |
| 71 | Back Pain Due to Lumbar Gouty Flare – A Prospective Diagnosis. <i>Journal of Rheumatology</i> , 2013, 40, 1459-1460. | 2.0 | 2 |
| 72 | Rapid crystal dissolution in gout: is it feasible and advisable?. <i>International Journal of Clinical Rheumatology</i> , 2014, 9, 395-401. | 0.3 | 2 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 73 | Comment on: The validation of a diagnostic rule for gout without joint fluid analysis: a prospective study. <i>Rheumatology</i> , 2015, 54, 1328-1329. | 1.9 | 2 |
| 74 | SUA levels should not be maintained ≤ 3 mg/dL for several years. Response to EULAR gout treatment guidelines by Richette et al: uric acid and neurocognition by Singh et al. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, e21-e21. | 0.9 | 2 |
| 75 | Synovial Fluid Crystal Analysis. , 2012, , 20-34. | | 1 |
| 76 | Effects of Xanthine Oxidase Inhibitors on Cardiovascular Disease in Patients with Gout: Ascertaining the Efficacy of Treatment Matters. <i>American Journal of Medicine</i> , 2015, 128, e41-e42. | 1.5 | 1 |
| 77 | Gout mimicking rheumatoid arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2016, 45, e28. | 3.4 | 1 |
| 78 | Clinical Images: Hematoidin in Synovial Fluid. <i>Arthritis and Rheumatology</i> , 2017, 69, 836-836. | 5.6 | 1 |
| 79 | Inflammatory status and uricaemia determine HDL-cholesterol levels in hypertensive adults over 65: an analysis of the FAPRES register. <i>Rheumatology International</i> , 2017, 37, 941-948. | 3.0 | 1 |
| 80 | SAPHO Presenting with a Lesion in the Symphysis Pubis. <i>Journal of Clinical Rheumatology</i> , 1998, 4, 28-31. | 0.9 | 0 |
| 81 | Diagnosis of Intercritical Gout. <i>Annals of Internal Medicine</i> , 2000, 132, 843. | 3.9 | 0 |
| 82 | Artrocentesis de la primera articulaci3n metatarsofal3ngica. <i>Seminarios De La Fundaci3n Espa3ola De Reumatolog3a</i> , 2007, 8, 127-129. | 0.1 | 0 |
| 83 | Gout and the heart: beyond comorbidities. <i>International Journal of Clinical Rheumatology</i> , 2015, 10, 329-334. | 0.3 | 0 |
| 84 | Urate crystals and inflammation. Cardiovascular impact of gout. <i>International Journal of Cardiology</i> , 2018, 271, 295. | 1.7 | 0 |
| 85 | Crystal Analysis in Synovial Fluid. , 2019, , 47-58. | | 0 |
| 86 | Gout. <i>Journal of Clinical Rheumatology</i> , 2020, 26, 208-212. | 0.9 | 0 |
| 87 | A small dose of intraarticular triamcinolone plus mepivacaine provides a rapid and sustained relief for gout flares. <i>Reumatolog3a Cl3nica</i> , 2022, 18, 129-130. | 0.5 | 0 |
| 88 | A small dose of intraarticular triamcinolone plus mepivacaine provides a rapid and sustained relief for gout flares. <i>Reumatolog3a Cl3nica (English Edition)</i> , 2022, 18, 129-130. | 0.3 | 0 |